MA38612A1 - Anticorps modifiés se liant au fcrn humain et procédés d'utilisation - Google Patents

Anticorps modifiés se liant au fcrn humain et procédés d'utilisation

Info

Publication number
MA38612A1
MA38612A1 MA38612A MA38612A MA38612A1 MA 38612 A1 MA38612 A1 MA 38612A1 MA 38612 A MA38612 A MA 38612A MA 38612 A MA38612 A MA 38612A MA 38612 A1 MA38612 A1 MA 38612A1
Authority
MA
Morocco
Prior art keywords
methods
human fcrn
modified antibodies
antibodies binding
binding
Prior art date
Application number
MA38612A
Other languages
English (en)
Inventor
Matthias Rueth
Guido Hartmann
Joerg Thomas Regula
Wolfgang Schaefer
Tilman Schlothauer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority claimed from PCT/EP2014/058417 external-priority patent/WO2014177460A1/fr
Publication of MA38612A1 publication Critical patent/MA38612A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne l'utilisation d'un anticorps comportant une région fc présentant une liaison nulle à fcrn pour le transport d'un ligand soluble du récepteur, à partir de l'œil à travers la barrière hémato-oculaire dans la circulation sanguine.
MA38612A 2013-04-29 2014-04-25 Anticorps modifiés se liant au fcrn humain et procédés d'utilisation MA38612A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13165744 2013-04-29
PCT/EP2014/058417 WO2014177460A1 (fr) 2013-04-29 2014-04-25 Anticorps modifiés se liant au fcrn humain et procédés d'utilisation

Publications (1)

Publication Number Publication Date
MA38612A1 true MA38612A1 (fr) 2018-01-31

Family

ID=48190316

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38612A MA38612A1 (fr) 2013-04-29 2014-04-25 Anticorps modifiés se liant au fcrn humain et procédés d'utilisation

Country Status (2)

Country Link
AR (1) AR096093A1 (fr)
MA (1) MA38612A1 (fr)

Also Published As

Publication number Publication date
AR096093A1 (es) 2015-12-02

Similar Documents

Publication Publication Date Title
EA201501063A1 (ru) СВЯЗЫВАЮЩИЕСЯ С ЧЕЛОВЕЧЕСКИМ FcRn МОДИФИЦИРОВАННЫЕ АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
MA34927B1 (fr) Anticorps anti-cea
MA43028B1 (fr) Anticorps bispécifiques pour pd1 et tim3
MA42530B1 (fr) Constructions d'anticorps bispécifiques se liant à dll3 et à cd3
WO2014055897A3 (fr) Anticorps monoclonaux humains anti pd-l1 et procédés d'utilisation
RU2017129721A (ru) АНТИТЕЛА ПРОТИВ αβTCR
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
MA35928B1 (fr) Thérapie combinée d'anticorps contre le csf -1r humain et ses utilisations
PE20121129A1 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana
EA201691438A1 (ru) Антитело, которое связывается с erbb-2 и erbb-3
EA200901119A1 (ru) АНТИТЕЛА ПРОТИВ ErbB3 И ИХ ПРИМЕНЕНИЕ
MA40913A (fr) Conjugués anticorps-médicament
MA34461B1 (fr) Anticorps anti-peptide beta-amyloide n3pgiu et leurs utilisations
EA201490745A1 (ru) Полипептиды антител, которые вызывают антагонизм cd40l
MA38797A1 (fr) Protéine de fusion thérapeutique
ATE497392T1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
EA201890078A1 (ru) Антитело
MX2016005686A (es) Ensayo de union competitiva al ligando para detectar anticuerpos neutralizantes.
MA38165A1 (fr) Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3
MA46988A1 (fr) Formulation liquide d'anticorps anti-tnf alpha
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3
MA38612A1 (fr) Anticorps modifiés se liant au fcrn humain et procédés d'utilisation
EA201892071A1 (ru) Способ профилактики болезни "трансплантат против хозяина"
MA43445A1 (fr) Anticorps modifies se liant au fcrn humain et procedes d'utilisation
SG11201901435UA (en) Monoclonal antibody against melk and utilization thereof